High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT

Lymphoma Clinical Trial

Official title:

2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03130582
• Other study ID #: 2015KY143
• Status: Completed
• Phase: N/A
• First received: April 22, 2017
• Last updated: April 26, 2017
• Start date: November 2005
• Est. completion date: December 2016

Study information

• Verified date: April 2017
• Source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2*108/kg for mononuclear cells and/or 2*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: December 2016
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 60 Years

Eligibility

Inclusion Criteria:

• relapsed/refractory lymphoma ,siut APBSCT

Exclusion Criteria:

• bone marrow without involvement by lymphoma cells

Related Conditions & MeSH terms

• Lymphoma

Intervention

Drug:
• high-dose etoposide
an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yang Jun

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	death	death	10 years
Primary	CR	Complete response	10 years
Primary	relapse	relapse	10 years